According to an experiment conducted by Scientists at the University of Texas at Austin, cancer drugs have the ability to restore the immune system, especially strengthening the ability to fight tumors.
This groundbreaking medical discovery will ensure that cancer is not the final call for people. Plus, the treatment will not weaken their body. The cancer drug which the scientists experimented with can reverse the immunity suppression caused by MTA. MTA is the major cell which causes the cancerous cell to affect one’s immunity. Methylthioadenosine (MTA) is a naturally occurring nucleoside with differential effects and affects normal and transformed cells.
However, this drug is claimed to boost immunotherapy effectiveness. On the other hand, it can also inhibit the growth of tumors. A period of experiments on mice with Melanoma and Leukemia showed a lack of tumor growth upon injecting this cancer drug.
Although immunotherapy is also a part of cancer treatment, with the help of the drug, you should be able to improve the treatment.
After their success with the experiment, the scientists published their journal, the Cancer Cell. The medical sphere feels quite confident about the drug bringing a positive and drastic change for Cancer treatment.
What Happens With The Affected Tumor When Injected With This Cancer Drug
There is a DNA segment called 9p21, which is deleted during cancerous treatment. This deletion of 9p21 has the worst effect on malignant cancer cells. Unfortunately, 25% to 50% of this DNA gets deleted when affected by mesothelioma and several brain tumors. With this, patients start getting resistance to immunotherapy treatment, which helps improve immunity while treating a tumor. (Source)
The deletion can also make detection difficult, making MTA release more toxic compounds, and worsening the cancer.
“In animal models, this cancer drug decreases the MTA down to its normal level making immunotherapy work on your immune system better.” a comment we took from Everett Stone, a Texas University research team research associate.